IS  >> Vol. 2 No. 2 (May 2014)

    外周血可溶性CD28含量与Graves疾病的相关性研究
    Correlation Analysis of Concentration of Plasma Soluble CD28 and Graves Disease

  • 全文下载: PDF(550KB) HTML    PP.11-16   DOI: 10.12677/IS.2014.22003  
  • 下载量: 2,036  浏览量: 8,204   国家自然科学基金支持

作者:  

孙中文:苏州市检验医学生物技术中心重点实验室,苏州;苏州卫生职业技术学院医学技术学院,苏州;
陶 鸿,黄静芳,易丽娴:苏州市检验医学生物技术中心重点实验室,苏州;
孙 静:苏州卫生职业技术学院医学技术学院,苏州;
陈 蕾:苏州市立医院内分泌科,苏州

关键词:
Graves病可溶性CD28分子相关性Graves’ Disease Soluble CD28 Correlation

摘要:

目的:探讨Graves病患者外周血中可溶性CD28分子浓度与FT3FT4sTSHTRAb等实验室参数的相关性,以分析外周血可溶性CD28分子含量测定对Graves病的临床辅助诊断价值。方法:采用双单抗夹心酶联检测法分析Graves病患者血液中可溶性CD28分子的含量;化学发光免疫法检测血液中甲状腺功能指标FT3FT4sTSH的浓度;ELISA法测定血液中TRAb的含量。结果:Graves病人血液中可溶性CD28分子含量(3.42 ± 0.74 ng/ml)明显高于健康对照组(0.83 ± 0.29 ng/ml) (p < 0.01);患者体内可溶性CD28分子的表达水平与FT3FT4TRAb浓度均呈正相关关系,相关系数γ分别为0.7860.7460.734,但可溶性CD28分子浓度与血清TSH表达呈显著负相关,相关系数γ−0.719;外周血液中可溶性CD28分子与Graves病患者甲状腺的肿大程度(p < 0.05)和突眼症(p < 0.01)均具有显著的正相关关系。结论:可溶性CD28分子参与了Graves疾病发生发展的病理过程,与FT3FT4sTSHTRAb均具有较好的相关性,可作为Graves病临床辅助诊断和疗效评估的重要生物学参数
Objective: We did this research to discuss the clinical importance of measuring plasma soluble CD28 in Graves’ disease, and explore correlation of soluble CD28 and FT3, FT4, sTSH, TRAb of plasma from Graves disease, and analyze diagnostic value of soluble CD28 in Graves’ disease. Me- thods: Using the sandwich ELISA for detecting soluble CD28 and TRAb levels in plasma from healthy donors and patients with Graves’ disease, we analyze the concentrations of FT3, FT4, sTSH through chemiluminescence immunoassay, simultaneously. Results: Our results have suggested that mean concentrations of soluble CD28 detected in patients with Graves’ disease (3.34 ± 0.62 ng/ml) were significantly higher than those in healthy subjects (0.76 ± 0.21 ng/ml) (p < 0.01). Moreover, there was a significantly positive correlation between the concentrations of soluble CD28 inplasma and levels of FT3 (r = 0.786, p < 0.01), FT4 (r = 0.746, p < 0.01), and TRAb (r = 0.734, p < 0.01) in plasma, but negative correlation was found between sCD28 levels and serum TSH (r =0.719, p < 0.01). High soluble CD28 levels (>5 ng/ml) in plasma of peripheral blood of some Graves patients had significant positive correlation with goiter (p < 0.05) and exophthalmos (p < 0.01). Conclusion: The soluble CD28 had higher levels in patients with Graves’ disease than those in healthy donors, and revealed positive correlation with FT3, FT4, TRAb. Therefore, soluble CD28 can be considered as an important biological parameter to support the diagnosis of Graves’ disease.

文章引用:
孙中文, 陶鸿, 孙静, 黄静芳, 易丽娴, 陈蕾. 外周血可溶性CD28含量与Graves疾病的相关性研究[J]. 免疫学研究, 2014, 2(2): 11-16. http://dx.doi.org/10.12677/IS.2014.22003

参考文献

[1] Graves, P.N., Vlase, H., Bobovnikova, Y., et al. (1996) Multimeric complex formation by the thyrotropin receptor in solubilized thyroid membranes. Endocrinology, 137, 3915-3920.
[2] Tada, H., Mizuta, L., Takano, T., et al. (2003) Blocking-type anti-TSH receptor antibodies and relation to responsiveness to anti-thyroid drug therapy and remission in Graves’ disease. Clinical Endocrinology, 58, 403-408.
[3] Markovic-Plese, S., Cortese, I., Wandinger, K.P., et al. (2001) CD4+CD28− costimulation-independent T cells in multiple sclerosis. Journal of Clinical Investigation, 108, 1185-1194.
[4] Nakajima, T., Schulte, S., Warrington, K.J., et al. (2002) T-Cell-Mediated lysis of endothelial cells in acute coronary syndromes. Circulation, 105, 570-575.
[5] Komocsi, A., Lamprecht, P., Csernok, E., et al. (2002) Peripheral blood and granuloma CD4(+)CD28(−) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener’s granulomatosis. American Journal of Pathology, 160, 1717-1724.
[6] Duftner, C., Goldberger, C., Falkenbach, A., et al. (2003) Prevalence, clinical relevance and characterization of cirlulating cytotoxic CD4+CD28T cells in ankylosing spondylitis. Arthritis Research & Therapy, 5, R292-R300.
[7] 史进芳, 顾国浩, 孙中文, 等 (2006) 膜型和可溶性CD28分子在衰老过程中的调节性表达. 中华老年医学杂志, 25, 288-289.
[8] 孙中文, 邱玉华, 马泓兵, 等 (2006) 可溶性人细胞分化抗原28分子酶联免疫试剂盒的研制及应用. 中华检验医学杂志, 29, 518-521.
[9] Hebbar, M., Jeannin, P., Magistrelli, G., et al. (2004) Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren’s syndrome and systemic sclerosis. Clinical & Experimental Immunology, 136, 388-392.
[10] Ip, W.K., Wong, C.K., Leung, T.F., et al. (2005) Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. International Archives of Allergy and Immunology, 137, 45-52.
[11] Sakthivel, P., Shively, V., Kakoulidou, M., et al. (2007) The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm. Journal of Internal Medicine, 261, 399407.
[12] Wong, C.K., Lit, L.C., Tam, L.S., et al. (2005) Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology, 44, 989-994.
[13] Wong, C.K., Lun, S.W.M., Ko, F.W.S., et al. (2005) Increased expression of plasma and cell surface costimolatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clinical & Experimental Immunology, 141, 122-129.